Ignite Creation Date:
2025-12-25 @ 2:31 AM
Ignite Modification Date:
2026-06-25 @ 1:08 AM
Study NCT ID:
NCT04638634
Status:
TERMINATED
Last Update Posted:
2021-12-10
First Post:
2020-11-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
Sponsor:
CSL Behring
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Coronavirus Disease 2019 (COVID-19) | View |
Keywords: